Related Experiment Video
Updated: Apr 16, 2026

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
Published on: August 1, 2016
Phosphorylation of cardiac Myosin-binding protein-C is a critical mediator of diastolic function
Paola C Rosas1, Yang Liu1, Mohamed I Abdalla1
1From the Department of Medical Physiology (P.C.R., Y.L., M.I.A., B.M.M., C.W.T.) and Division of Molecular Cardiology, Department of Medicine (C.M.T., R.K., K.M.B.), Texas A&M University Health Science Center, College of Medicine, Temple City; Internal Medicine/Division of Cardiology (D.T.K., C.W.T.) and Department of Surgery (G.F.D., D.M.), Baylor Scott & White Health-Central Texas, Temple City; Department of Cell and Regenerative Biology and Biotechnology Center, University of Wisconsin School of Medicine and Public Health, Madison (P.A.P., D.P.F., R.L.M.); and Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois, Chicago (B.G.P., C.M.W., R.J.S.).
Insights
Phosphorylation of cardiac myosin-binding protein-C (cMyBP-C) enhances heart muscle relaxation, crucial for treating heart failure with preserved ejection fraction (HFpEF). Deficient cMyBP-C phosphorylation leads to diastolic dysfunction, a hallmark of HFpEF.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Heart failure with preserved ejection fraction (HFpEF) affects nearly 50% of heart failure cases and lacks effective treatments.
- Diastolic dysfunction is the primary mechanism underlying HFpEF, necessitating research into relaxation-mediating pathways.
- Cardiac myosin-binding protein-C (cMyBP-C) is a key thick filament protein regulating cross-bridge cycling through its phosphorylation status.
Purpose of the Study:
- To investigate the functional role of cMyBP-C phosphorylation in regulating myocardial relaxation and diastolic function.
- To determine if alterations in cMyBP-C phosphorylation contribute to the development of HFpEF phenotypes.
- To explore cMyBP-C as a potential therapeutic target for HFpEF.
Main Methods:
- Comparison of mouse models with wild-type, phosphorylation-deficient (t3SA), and phosphomimetic (t3SD) cMyBP-C.
- Assessment of cardiac function using echocardiography and pressure/volume measurements.
- Analysis of myocardial relaxation rates and intracellular calcium handling via papillary muscle experiments.
Main Results:
- Mice with phosphorylation-deficient cMyBP-C (t3SA) exhibited reduced running capacity, increased lung/body weight ratios, and elevated brain natriuretic peptide levels, indicative of heart failure.
- Phosphorylation-deficient cMyBP-C (t3SA) mice showed impaired myocardial relaxation and diastolic dysfunction, consistent with HFpEF.
- Phosphomimetic cMyBP-C (t3SD) mice demonstrated enhanced myocardial relaxation, while the underlying mechanism was attributed to altered cross-bridge detachment rates, not changes in calcium handling.
Conclusions:
- cMyBP-C phosphorylation is essential for enhancing myocardial relaxation and maintaining diastolic function.
- Deficient cMyBP-C phosphorylation leads to diastolic dysfunction and HFpEF-like phenotypes.
- Targeting cMyBP-C phosphorylation presents a promising therapeutic strategy for treating HFpEF.
Background:
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for ≈50% of all cases of HF and currently has no effective treatment. Diastolic dysfunction underlies HFpEF; therefore, elucidation of the mechanisms that mediate relaxation can provide new potential targets for treatment. Cardiac myosin-binding protein-C (cMyBP-C) is a thick filament protein that modulates cross-bridge cycling rates via alterations in its phosphorylation status. Thus, we hypothesize that phosphorylated cMyBP-C accelerates the rate of cross-bridge detachment, thereby enhancing relaxation to mediate diastolic function.
Methods And Results:
We compared mouse models expressing phosphorylation-deficient cMyBP-C(S273A/S282A/S302A)-cMyBP-C(t3SA), phosphomimetic cMyBP-C(S273D/S282D/S302D)-cMyBP-C(t3SD), and wild-type-control cMyBP-C(tWT) to elucidate the functional effects of cMyBP-C phosphorylation. Decreased voluntary running distances, increased lung/body weight ratios, and increased brain natriuretic peptide levels in cMyBP-C(t3SA) mice demonstrate that phosphorylation deficiency is associated with signs of HF. Echocardiography (ejection fraction and myocardial relaxation velocity) and pressure/volume measurements (-dP/dtmin, pressure decay time constant τ-Glantz, and passive filling stiffness) show that cMyBP-C phosphorylation enhances myocardial relaxation in cMyBP-C(t3SD) mice, whereas deficient cMyBP-C phosphorylation causes diastolic dysfunction with HFpEF in cMyBP-C(t3SA) mice. Simultaneous force and [Ca(2+)]i measurements on intact papillary muscles show that enhancement of relaxation in cMyBP-C(t3SD) mice and impairment of relaxation in cMyBP-C(t3SA) mice are not because of altered [Ca(2+)]i handling, implicating that altered cross-bridge detachment rates mediate these changes in relaxation rates.
Conclusions:
cMyBP-C phosphorylation enhances relaxation, whereas deficient phosphorylation causes diastolic dysfunction and phenotypes resembling HFpEF. Thus, cMyBP-C is a potential target for treatment of HFpEF.
More Related Videos
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Cross-bridge Cycle
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Nitric Oxide Signaling Pathway

